Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-30 | Dr. Eric J. Ende, age 50, has been a member of the Board of Directors since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group... Dr. Ende brings to the Board, Audit Committee and Compensation Committee over 20 years of experience in the pharmaceutical and life sciences industries. |
| 2020-04-27 | Dr. Eric J. Ende, 51, has been a member of the Board of Directors since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately-held consulting company focused on the life sciences industry, a position he has held since 2009. Since November 2019, Dr. Ended has been a member of the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company, where he also serves as the chair of the compensation committee and is a member of the audit and science committees. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit Committee. |
| 2021-04-30 | Dr. Eric J. Ende, 52, Director, Committees: (2)(4*), Compensation: $297,434 |
| 2022-04-29 | Dr. Eric J. Ende, 53, has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit Committee. Dr. Ende also serves on the board of directors at Neubase Therapeutics and at Mount Sinai Innovation Partners Technology. |
| 2023-04-28 | Dr. Eric J. Ende, 54, has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he is currently Chairman of the Board in addition to serving on the Nominating and Corporate Governance Committee. Dr. Ende also serves on the board of directors at Neubase Therapeutics, a company focused on genetic medicines development, and at Mount Sinai Innovation Partners Technology, a healthcare research and development organization. |
| 2024-06-18 | Dr. Eric J. Ende, 55, has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. The Board has an Audit Committee composed of Peter J. Thornton (Chair), Dr. Eric J. Ende, Geoffrey M. Glass and Dr. Mark A. McCamish. The Board has a Nominating and Corporate Governance Committee, composed of Dr. Eric J. Ende (Chair), Geoffrey M. Glass and Linda S. Palczuk. |
Data sourced from SEC filings. Last updated: 2026-02-08